By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


CSL Behring 

1020 First Avenue
P.O. Box 61501
King of Prussia  Pennsylvania  19406-0901  U.S.A.
Phone: 610-878-4000 Fax: 610-878-4009



Company News
U.S. FDA Approves CSL Behring's AFSTYLA-- The First And Only Recombinant Factor VIII Single Chain Therapy For Hemophilia A 5/27/2016 6:24:46 AM
European Commission (EC) Approves IDELVION --CSL Behring's Novel Hemophilia B Treatment With Up To 14-Day Dosing Intervals 5/11/2016 11:17:28 AM
CSL Behring CEO Paul Perreault Focuses On Patient-Centric Leadership In Pharma 5/3/2016 10:25:23 AM
CSL Behring Commemorates 100 Years Of Delivering On Its Promise To Develop Innovative Therapies For People With Life-Threatening Medical Conditions 4/25/2016 10:06:31 AM
CSL Behring Marks World Hemophilia Day By Donating Ius Of Its Specialty Biotherapeutics For Bleeding Disorders To World Federation Of Hemophilia 4/13/2016 8:38:23 AM
CSL Behring Release: IDELVION For Hemophilia B Now Available In The U.S. 3/21/2016 7:25:58 AM
CSL Behring Sponsors IDF Webinar Series For Young Adults Living With Primary Immunodeficiencies 3/15/2016 10:02:13 AM
Albumedix Drug Delivery Technology Used By CSL Behring To Achieve 14 Day Dosing For Hemophilia B Therapy 3/15/2016 9:49:23 AM
CSL Behring Awards LEAD Grants To Help Rare Disease Patient Groups Achieve Their Advocacy Objectives 3/9/2016 7:24:24 AM
FDA Green Lights CSL Behring's Idelvion for Hemophilia B 3/7/2016 6:08:35 AM